# High Field

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/high-field

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Total disclosed funding: $16M
- Latest round: Series B (Dec 22, 2021)
- Investors on record: 6

## About

Established in 2013 and based in Hangzhou, China, High Field is a biomedical company that focuses on the development of innovative lipid nano drugs. Dr. Yuhong Xu, the company’s founder and CSO, served as a preparation researcher at Chiron Corp and the director of translational medicine at GSK (Shanghai) R&D Center.

The company engages in the development of innovative lipid nano drugs. It has three major lipid technology platforms: small molecule liposomes, antibody-conjugated liposomes and nucleic acid lipid nanoparticles. Its main product is mRNA vaccine. The company's products are used in the treatment of tumors, autoimmune and metabolic diseases.

## Funding rounds

- Series B, Dec 22, 2021, $16M — Hiway Capital, Tigermed, HFI Industry Fund Management, Firstlight Capital, Shaoxing Minsheng Pharmaceutical Co., Ltd.
- Series A, Sep 10, 2019 — Hiway Capital, Tigermed
- Angel, Dec 15, 2017 — Bohe Angel Fund

## Investors

- Bohe Angel Fund — Angel
- Hiway Capital (https://capitalatlas.ai/funds/hiway-capital) — Series A, Series B
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series A, Series B
- HFI Industry Fund Management (https://capitalatlas.ai/funds/hfi-industry-fund-management) — Series B
- Firstlight Capital — Series B
- Shaoxing Minsheng Pharmaceutical Co., Ltd. — Series B